Nature of the Business and Basis of Presentation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands |
|
|
1 Months Ended |
12 Months Ended |
Oct. 09, 2014 |
Sep. 22, 2014 |
Sep. 30, 2014 |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
| Proceeds from initial public offering, net of underwriting discounts and commissions |
|
|
|
|
$ 97,929
|
|
| Number of common shares issued on conversion of redeemable convertible preferred stock |
|
14,860,173
|
14,860,173
|
|
|
|
| Accumulated deficit |
|
|
|
$ (131,438)
|
$ (86,351)
|
|
| Cash and investments |
|
|
|
$ 63,957
|
|
|
| Ownership interest |
|
|
|
0.00%
|
|
|
| Option to Purchase Additional Shares of Common Stock Granted to the Underwriters in Connection with the IPO [Member] |
|
|
|
|
|
|
| Common Stock, shares issued and sold |
540,000
|
|
|
|
|
|
| Common stock, public offering price per share |
$ 15.00
|
|
|
|
|
|
| Proceeds from initial public offering, net of underwriting discounts and commissions |
$ 7,533
|
|
|
|
|
|
| Common Stock [Member] |
|
|
|
|
|
|
| Number of common shares issued on conversion of redeemable convertible preferred stock |
|
|
|
|
14,860,173
|
|
| Common Stock [Member] | IPO [Member] |
|
|
|
|
|
|
| Common Stock, shares issued and sold |
|
6,480,000
|
|
|
7,020,000
|
|
| Common stock, public offering price per share |
|
$ 15.00
|
|
|
|
|
| Proceeds from initial public offering, net of underwriting discounts and commissions |
|
$ 87,062
|
|
|
|
|
| Diotima Pharmaceuticals Inc [Member] |
|
|
|
|
|
|
| Expenses incurred by Diotima |
|
|
|
|
$ 8
|
$ 60
|